<DOC>
	<DOCNO>NCT02086656</DOCNO>
	<brief_summary>Capecitabine , oxaliplatin , irinotecan bevacizumab perioperative strategy borderline and/or high risk resectable colorectal cancer liver metastasis</brief_summary>
	<brief_title>PERIOPERATIVE TREATMENT WITH COI-B ( CAPECITABINE , OXALIPLATIN , IRINOTECAN AND BEVACIZUMAB ) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES</brief_title>
	<detailed_description>Previous study demonstrate significant association tumor regression grade hepatic colorectal metastasis ( TRG1 : complete pathological response ; TRG2 : major pathological response ; TRG3 : partial pathological response ; versus TRG4-5 pathological response ) outcome term survival neoadjuvant treatment . In particular , retrospective data show association oxaliplatin-based chemotherapy improvement grade percentage tumor regression ; moreover , addition Bevacizumab seem improve TRG chemotherapy alone , confer also protection liver damage due chemotherapy-induced sinusoidal obstruction syndrome . This rationale induce u carry evaluation feasibility assessment perioperative approach COI-B regimen patient affect high risk borderline resectable colorectal liver metastasis , without previous resection primary tumor .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Inclusion criterion : Histological diagnosis colorectal adenocarcinoma . Liverlimited metastasis metastasis mainly ( â‰¥80 % total disease burden ) limit liver extrahepatic disease judge resectable concomitantly sequentially . Primary tumor may resect , patient must symptomatic T. Previous adjuvant therapy allow terminate least 6 month . Previous first line treatment ( irinotecan oxaliplatin contain regimen ) stable partial response 3 month treatment Age &gt; = 18 year Performance Status ( ECOG &lt; 2 ) Adequate organ function include follow : Adequate bone marrow reserve : WBC count &gt; 3.0x109/L , absolute neutrophil count &gt; 1.5x109/L , platelet count &gt; 100x109/L , hemoglobin &gt; 10 g/dL . Hepatic : bilirubin &lt; 1.5 time ULN , alkaline phosphatase , aspartate transaminase , alanine transaminase &lt; 2.5 xULN Renal : serum creatinin &lt; 2.0xULN Patients compliance geographic proximity allow adequate followup Patients must sign informed consent document ( ICD ) Male female patient reproductive potential must use approved contraceptive method . Tumor involvement liver &gt; 75 % Chance liver remnant surgery &lt; 25 % Eligibility concurrent radiotherapeutic treatment Disease progression first line chemotherapy FOLFOX , XELOX , FOLFIRI XELIRI plus bevacizumab Previous treatment 3 month FOLFOX FOLFIRI Previous therapy bevacizumab cetuximab panitumumab Administration experimental drug study . Body Mass Index &gt; 35 Brain metastasis . Pregnancy breastfeed . Serious uncontrolled medical pathology active infection would jeopardize possibility receive investigated treatment . Disorders could influence absorption capecitabine ( e.g . malabsorption ) , intestinal occlusion , Crohn 's disease ulcerative colitis . Psychiatric disorder , neurologic disease condition would make impossible comply protocol procedure . Peripheral neuropathy relate oxaliplatin previous administration . Previous dangerous life threaten toxicity fluoropyrimidine . Positive anamnesis regard neoplastic disease except one cure 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>perioperative treatment</keyword>
</DOC>